KRAS and lung cancer: it was described the genomic landscape of patients with lung cancer (n = 997) with NGS in a Canadian hospital, founding a higher prevalence of KRAS mutations (39.2%) compared with most geographical locations, which proved the important to assess institutional rates of actionable driver mutations to help guide governing bodies.24